Updates are available Correction dated 2022-10-10
Click to view Correction: https://doi.org/10.1038/s41591-022-02066-w
-
Authors
Mielke, Michelle M. http://orcid.org/0000-0001-7177-1185
Dage, Jeffrey L. http://orcid.org/0000-0002-2192-1699
Frank, Ryan D.
Algeciras-Schimnich, Alicia
Knopman, David S. http://orcid.org/0000-0002-6544-066X
Lowe, Val J.
Bu, Guojun http://orcid.org/0000-0003-3491-1016
Vemuri, Prashanthi http://orcid.org/0000-0003-4286-0589
Graff-Radford, Jonathan
Jack, Clifford R. Jr http://orcid.org/0000-0001-7916-622X
Petersen, Ronald C.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (U01 AG006786, R37 AG011378, P30 AG062677, R01 AG041851, R01 AG034676)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01 NS097495)
- License Information
-
More Information
Article History
Received: 3 January 2022
Accepted: 11 April 2022
First Online: 26 May 2022
Change Date: 10 October 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-022-02066-w
Competing interests
: M.M.M. has served as a consultant for Biogen, Brain Protection Company and Labcorp. J.L.D. was previously an employee and is still a minor shareholder of Eli Lilly and Company. J.L.D. is an inventor on patents or patent applications of Eli Lilly and Company relating to the assays, methods, reagents and/or compositions of matter used in this work. J.L.D. has also served as a consultant for Karuna Therapeutics and received research support from ADx Neurosciences, Roche Diagnostics and Eli Lilly and Company. R.D.F. and A.A.-S. report no conflicts. D.S.K. serves on a data safety monitoring board for the Dominantly Inherited Alzheimer Network (DIAN) study. D.S.K. also serves on a data safety monitoring board for Biogen but receives no personal compensation. D.S.K. is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California. D.S.K. serves as a consultant for Roche, Samus Therapeutics, Third Rock and Alzeca Biosciences but receives no personal compensation. V.J.L. received consulting fees from Bayer Schering Pharma, Piramal Life Sciences and Merck Research, and grants from GE Healthcare, Siemens Molecular Imaging, Avid Radiopharmaceuticals and the NIH. G.B. serves as a consultant for AbbVie, E-Scape and SciNeuro. P.V. received speaking fees from Miller Medical Communications. J.G.-R. receives NIH funding and serves as an assistant editor for <i>Neurology</i>. C.R.J. serves on an independent data monitoring board for Roche, has served as a speaker for Eisai and consulted for Biogen but receives no personal compensation from any commercial entity. C.R.J. receives research support from the NIH and the Alexander Family Alzheimer’s Disease Research Professorship of Mayo Clinic. R.C.P. received consulting fees from Hoffman-La Roche, Merck, Genentech, Biogen, GE Healthcare and Eisai.
